Cohort Study

Statin Induced Myopathy Among Patients Attending the National Center for Diabetes, endocrinology, & genetics

Waddah Abed a, Mousa Abujbara a, Anwar Batieha b, Kamel Ajlouni a, b

a Department of Endocrinology, The National Center (Institute) for Diabetes, Endocrinology, and Genetics, The University of Jordan, Amman, Jordan
b Department of Public Health, Jordan University of Science and Technology (JUST), Irbid, Jordan

ARTICLE INFO

Keywords:
Myalgia
Statin
Incidence
CPK
Myopathy-Statin intolerance
HMG-CoA

ABSTRACT

Background and objectives: myopathy is a major side effect of statins that leads to statin intolerance and discontinuation. In this prospective cohort study, the main objective was to estimate the incidence of myopathy in patients receiving statins. In addition, we identified some risk factors associated with statin induced myopathy.

Methods: A prospective cohort study was conducted at the National Center for Diabetes, Endocrinology and Genetics (NCDEG) in Jordan from October 1, 2018 to January 31, 2021. All subjects who initiated statin therapy followed up during that period. Data was collected at time 0 (baseline), 3, 6, 9, and 12 months after enrollment. Demographic and clinical data were collected from medical records. Muscular symptoms were collected by conducting face-to-face interviews to all patients using a pre-structured questionnaire.

Results: The overall incidence of myopathy among patients taking statins was 27.8%, 31.4% in males and 22.6% in females, the incidence of myopathy was higher in older people, being highest in patients ≥60 years (34%). Bivariate analyses showed no significant association between myopathy and hypothyroidism, diabetes or medications that are known to interact with statins. The incidence of myopathy was highest with Simvastatin 40 mg (50%) and lowest with Fluvastatin XL 80 mg (8%) and Rosuvastatin 10 mg (10.8%).

Conclusions: The overall incidence of myopathy in patients taking statins was 27.8%. Myopathy was directly related to dose and type of statin used. The use of Fluvastatin XL 80 mg and Rosuvastatin 10 mg showed less incidence of myopathy compared with other statins.

1. Introduction

Cardiovascular diseases are considered the leading cause of morbidity and mortality worldwide, with the major cause being the formation of lipid plaques in coronary arteries. High plasma level of total cholesterol and low-density lipoprotein (LDL) are well-established risk factors for ischemic heart disease [1,2]. Statins (HMG-CoA Reductase Inhibitors) have been proven to efficiently lower serum concentration of total cholesterol and LDL. Apart from lipid lowering properties, statins have also other beneficial effects on cardiovascular events, including improvement of endothelial function, reduction of smooth muscles proliferation, and modification of inflammatory responses. Accordingly, statins are considered a cornerstone in both the primary and secondary prevention of cardiovascular diseases [3–5].

Statins are generally safe and well tolerated; however, they can be associated with various adverse effects. Myopathy is recognized as the most common adverse effect associated with statin therapy [6], ranging from myalgia (muscle symptoms without creatinine kinase elevation) to myositis (muscle symptoms with increased creatinine kinase level). In rare situations, it can worsen to life threatening rhabdomyolysis (muscle symptoms with marked elevation of creatinine kinase and myoglobinuria) [7]. The incidence of statins induced myopathy reported in previous studies ranged from 5% to 20% dependent on the criteria of diagnosis of myopathy and the type of study [8–12]. Since adherence to statin therapy can be limited by myopathy, and given the more aggressive approach to lipid-lowering therapy advocated by recent treatment guidelines, better understanding of the nature of statin induced myopathy is of considerable importance [13,14].

The main objective of this study is to estimate the incidence of myopathy in patients receiving statin therapy over 12 months of follow-up.
up. In addition, we explored a possible association between myopathy and a number of factors that may increase that risk.

2. Subjects and methods

This prospective cohort study was conducted at the National Center for Diabetes, Endocrinology, and Genetics (NCDEG) in Amman, Jordan, from October 1, 2018 to January 31, 2021. All adult patients, 18 years old or above, who initiated statins therapy during the above-mentioned period were invited to participate in the study. Clinical charts, nursing records, and laboratory findings were reviewed. Demographic data, medical history, underlying comorbidities, medications profile, and laboratory findings were extracted. The type and dose of statin used, and other concomitant medications, with particular consideration of drugs known to interact with statins were obtained.

All patients were interviewed by the principle author using a pre-structured questionnaire. The questionnaire included onset, nature, and location of muscle symptoms after statin therapy initiation, in addition to lifestyle factors including degree of exercise, dietary habits and alcohol intake. The questionnaire and laboratory investigations, including creatine kinase (CK) level, lipid profile, thyroid function tests, vitamin D level, liver function test, and creatinine level were conducted at baseline before starting statin therapy and repeated at months 1, 3, 6, and 12 after initiation of statin therapy.

We adapted the American College of Cardiology (ACC), the American Heart Association (AHA), and the National Heart, Lung, and Blood Institute (NHLBI) for myopathy and related terms definitions [15]. The incidence of Statin-induced myopathy was calculated by dividing the number of patients who developed muscular symptoms and/or CK elevation after starting statin therapy to the total number of patients.

All patients who had muscular pain prior the initiation of statin, creatinine level more than two mg/dl (normal range 0.5–0.9 mg/dl), alanine transaminase (ALT) level more than two times the upper limit of normal (normal range 0–33 mg/dl), inherited or metabolic muscle or joint diseases were excluded.

3. Ethical considerations

An informed consent was obtained from the recruited patients. All procedures performed in this study involving human participants were reviewed and ethically approved by the Institutional Review Board (IRB) and research and ethics committee at NCDEG, Amman, Jordan. This study was conducted following the 1975 Helsinki declaration, as revised in 2008 and its later amendments or comparable ethical standards.

4. Statistical analysis

Data was entered and analyzed using the Statistical Package for Social Science (SPSS version 21). The overall incidence of myopathy was calculated as well as the incidence in subgroups defined by relevant variables. The bivariate association between myopathy and a number of variables was assessed for statistical significance using the chi square test. A P-value of <0.05 was considered statistically significant.

5. Results

The population of our study was 465 subjects, 400 completed the study (59.0% males and 41.0% females) with a mean age ± SD of 54.2 ± 10.3 years. The remaining 65 patients dropped out due to poor compliance or lost follow up.

Their demographic information and clinical characteristics are summarized in Table 1. The most common age group was between 50 and 59 years old (41%). Most of the patients in this study were either obese or overweight (87%), and the mean (SD) BMI for the study participants was 32.2. Around 70% of the studied population were nonsmokers, while 21% were current smokers. Sixty nine percent of patients were diabetics, 53% were hypertensive, 7.8% had coronary artery diseases, 12.8% had hypothyroidism and 3% had osteoporosis (see Table 2).

The overall incidence of statin induced myopathy was 27.8% (n = 111). Evaluation of myopathy with respect to gender and age groups is depicted in Table- 3. Although there was no significant association between myopathy and gender, myopathy was more prevalent in males (31.4%) in comparison to females (22.6%). The incidence of myopathy increased with increased age. In age group 40–49 years, 26.6% developed myopathy, in 50–59 age group, 28.7% developed myopathy, whereas in 60–79 age group, 34.0% developed myopathy but without significant association between age and incidence of myopathy.

During the observation period, the incidence of myopathy was found to be in 81 (20.2%), 39 (9.9%), 13 (4.5%) and 7 (3.8%), respectively during the observation period (1, 3, 6 and 12 months) (see Table 3). Presence of myalgia with respect to dose of statin is depicted in Table 4. Incidence of myopathy in patients who took Fluvastatin XR 80 mg was the lowest (8%), whereas the highest incidence of myopathy was among the group who took simvastatin 40 mg (50%). Rosuvastatin 10 mg had the lowest risk of myopathy after Fluvastatin (10.8%) whereas the incidence of myopathy in patients who took Rosuvastatin 20 mg was 14.6%. The incidence of myopathy for atorvastatin 10 mg, 20 mg, 40 mg was 12.5%, 21.2%, and 28.9% respectively (see Table 5).

No significant differences were found in risk factors associated with statin induced myopathy in terms of hypothyroidism, diabetes mellitus, Ca channel blockers, Allopurinol and Fibrate as shown in Table 4.
actual rate of this side effect and may not be generalized to community exclusion criteria where patients with comorbidities that would predispose based clinical practice settings [7,8], this may be explained by the in-

- differences, Jordan, 2021.
- Incidence of myopathy by selected variables and the significance of observed to an increased risk of statin induced myopathy may be
- also suggests that the incidence rate of statin induced myopathy, study was much higher compared to most previous reports [7]. This is consistent with Gregory A et al. study [10], which reported the rate of myopathic events in over 30,000 subjects, classified into diabetic and non-diabetic, over a 9-year period, and showed that diabetes confers a higher rate of muscular symptoms in patients using statins (21%). The relatively high rate of statin induced myopathy in our population found in these studies may point to the importance of genetic factors, cultural variations in reporting side effects of medications, and/or possibly dietary factors interacting with statins.

Many factors have been reported as risk factors for statin induced myopathy, such as old age, low BMI, comorbidities (such as hypothyroidism, diabetes and renal impairment), concomitant medications known to interact with the metabolism of statins, (such as Fibrate, Clexsporin, Calcium channel blockers, and macrolide antibiotics), alcohol abuse and even large quantities of grapefruit juice are also considered independent risk factors, although epidemiological data is conflicting in regard to this or these associations [20,21]. In our study we did not find any significant association between myopathy and hypothyroidism or medications such as fibrate, allopurinol, or calcium channel blockers. Although the risk increased with age, and the presence of comorbidities and polypharmacy, none of these attained statistical significance. Alcohol as a risk factor for statin induced myopathy couldn’t be assessed as almost all our subjects were non-drinker or denied that due to religious and cultural issues.

Although diabetes has been suggested as a possible risk factor for myopathy [22], our study showed no significant association between diabetes and the occurrence of muscular symptoms (29, 7% vs 27,8%). This is consistent with Gregory A et al. study [15], which reported the rate of myopathic events in over 30,000 subjects, classified into diabetic and non-diabetic, over a 9-year period, and showed that diabetes confers no additional myopathic risk. In regard to gender, we found that myopathy was more frequent in males than females (31, 4% vs 22, 6%). This difference was close to statistical significance (p value = 0.053), a finding that contradicts with Skiliving et al. [11] which showed that women had a higher frequency of myopathy than men (17% vs 12%).

Statin-induced myopathy is considered to be dose and type dependent [8]. Our results showed an association between dose of statin and occurrence of myopathy irrespective of the statin used. The most frequently used statin in our study was atorvastatin (53.3%) followed by Rosuvastatin (23.0%), Simvastatin (19.8%), and Fluvastatin XL (3.0%). The lowest myopathy (8%) was observed with Fluvastatin XL which is consistent with the PRIMO study [9].

The highest incidence of myopathy in our study was observed with simvastatin 40 mg (50%). This finding is consistent with the PRIMO study [9], in which the highest risk of muscular symptoms was observed with simvastatin therapy, though, again, at a lower rate (18%) than ours.

The risk of muscular symptoms for atorvastatin therapy was around 15% in the PRIMO study without mentioning the rates for different doses. In our study, rates of myopathy were dose-dependent: the higher the dose, the higher the rate of myopathy: 12,5% with atorvastatin 10
mg, 21.2% with atorvastatin 20 mg, and 28.4% with atorvastatin 40 mg. Rosuvastatin was the second most common statin used in our study (23%) after atorvastatin, and a dose of Rosuvastatin 10 mg carried the lowest risk of myopathy after Fluvastatin XL. Myopathy after Rosuvastatin was also dose dependent: 10.8% for a dose of 10 mg climbing up to 14.6% for a dose of 20 mg. According to James Shepherd et al. who evaluated Rosuvastatin in over 16,000 patients, myopathy was observed in 5.1% [23].

7. Limitations

The vast majority of the study subjects were taking atorvastatin and simvastatin, due to the high cost of other types of statins; accordingly, we could not compare the rate of muscular symptoms associated with different kinds and doses of statins. Similarly, we could not analyze some factors suggested to increase myopathy such as medications like cyclosporine and amiodarone, as they were infrequently prescribed. Another factor that we couldn’t analyze, was alcohol, as almost all our subjects were non-drinkers.

8. Conclusion

Muscular adverse reactions secondary to statin therapy are relatively common, and probably more common than previously reported in previous studies. To better understand the mechanism and the exact relationship between Old age, comorbidity, and polypharmacy and the risk of myopathy a large cohort studies are still needed.

Finally, our study showed that treating patients with statins associated with a lower risk of myopathy, such as Fluvastatin and Rosuvastatin, may increase compliance with these medications.

Ethical approval

An informed consent was obtained from the recruited patients. All procedures performed in this study involving human participants were reviewed and ethically approved by the Institutional Review Board (IRB) and research and ethics committee at NCDEG, Amman, Jordan. This study was conducted following the 1975 Helsinki declaration, as revised in 2008 and its later amendments or comparable ethical standards.

Sources of funding

This research was supported by NCDEG Research Fund.

Author contributions

Waddah Abed: wrote, supervised and edited the manuscript.
Mousa Abujbara: helped in developing the idea and setting the protocol and reviewed the manuscript.
Anwar Bateha: perform the statistical analysis and reviewed the manuscript.
Kamel Ajlouni: was the guarantor of this work and reviewed the manuscript.

All authors equally contributed to the study concept or design, data searching, data analysis or interpretation, writing the paper.

Registration of research studies

1. Name of the registry: Statin Induced Myopathy Among Patients Attending the National Center for Diabetes, Endocrinology and Genetics.
2. Unique Identifying number or registration ID: 7406.
3. Hyperlink to your specific registration (must be publicly accessible and will be checked): https://www.researchregistry.com/browse-the-registry#/home/

Guarantor

Prof. Kamel Ajlouni.

Consent

An informed consent was obtained from the recruited patients.

Provenance and peer review

Not commissioned, externally peer reviewed.

Declaration of competing interest

The authors declared that there is no conflict of interest.

Acknowledgements

All Staff members of NCDEG for their meticulous help.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.amsu.2022.103304.

References

[1] J. Fuhrmeister, M. Tews, A. Kromer, B. Moosmann, Prooxidative toxicity and selenoprotein suppression by cerivastatin in muscle cells, Toxicol. Lett. 215 (2012) 219–227, https://doi.org/10.1016/j.toxlet.2012.10.010. Epub 2012 Oct 22. PMID: 23092657.
[2] Z. Zhang, Z. Li, K. Cao, D. Fang, F. Wang, G. Bi, J. Yang, Y. He, J. Wu, Y. Wei, X. Song, Adjunctive therapy with statins reduces residual albuminuria/proteinuria and provides further renoprotection by downregulating the angiotensin II-AT1 pathway in hypertensive nephropathy, J. Hypertens. 35 (2017) 1442–1456, https://doi.org/10.1097/HJH.0000000000001225.
[3] The Lipid Research Clinics Coronary Primary Prevention Trial results. II, the relationship of reduction in incidence of coronary heart disease to cholesterol lowering, JAMA 251 (3) (1984) 365–374. PMID: 6361390.
[4] J.C. LaRosa, D. Hunninghake, D. Bush, M.H. Criqui, G.S. Getz, A.M. Gotto, L. Rakita, R.M. Robertson, M.L. Weisfeldt, The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association, Circulation 81 (5) (1990) 1721–1733, https://doi.org/10.1161/01. cir.81.5.1721.
[5] The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease, JAMA 251 (3) (1984) 351–364, https://doi.org/10.1001/jama.1984.03340270029025.
[6] R.B. Iwree, J. Hewitt, Myopathy in older people receiving statin therapy: a systematic review and meta-analysis, Br. J. Clin. Pharmacol. 80 (3) (2015) 363–371, https://doi.org/10.1111/bcp.12687.
[7] Scandinavian Simvastatin Survival Study Group, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet 344 (8934) (1994) 1383–1389. PMID: 7968073.
[8] M. Ucar, T. Mjørdal, R. Dahlqvist, HMG-CoA reductase inhibitors and myotoxicity, Drug Saf. 22 (2000) 441–457, https://doi.org/10.2165/00002018-200022060-00005.
[9] A. Kashani, C.O. Phillips, J.M. Foody, Y. Wang, S. Mangalurmi, D.T. Ko, H. M. Krumholz, Risks associated with statin therapy: a systematic overview of randomized clinical trials, Circulation 114 (2006) 2788–2797, https://doi.org/10.1161/CIRCULATIONAHA.106.624896.
[10] E. Bruckert, G. Hayem, S. Dejager, C. Yau, B. Begaud, Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study, Cardiovasc. Drugs Ther. 19 (6) (2005) 403–414, https://doi.org/10.1007/s10557-005-5686-z.
[11] G.A. Nichols, C.E. Kero, Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients, Clin. Therapeut. 29 (8) (2007) 1761–1770, https://doi.org/10.1016/j.clinthera.2007.08.022.
[12] I. Skilving, M. Eriksson, A. Rane, M.L. Overjo, Statin-induced myopathy in a usual care setting—a prospective observational study of gender differences, Eur. J. Clin. Pharmacol. 72 (10) (2016) 1171–1176, https://doi.org/10.1007/s00228-016-2105-2. Epub 2016 Aug 2.
[13] D.K. Arnett, R.S. Blumenthal, M.A. Albert, A.B. Bukorer, Z.D. Goldberg, E. J. Hahn, C.D. Himmelfarb, A. Khera, D. Lloyd-Jones, J.W. McCroy, E.D. Michos, M. D. Miedema, D. Munoz, S.C. Smith Jr., S.S. Virani, K.A. Williams Sr., J. Yeboah,
B. Ziaeian, 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary A report of the American College of Cardiology/American heart association task force on clinical practice guidelines, J. Am. Coll. Cardiol. 74 (10) (2019) 1376–1414, https://doi.org/10.1016/j.jacc.2019.03.009.

[14] H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, S. J. Livingston, et al., Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDs): multicentre randomised placebo-controlled trial, Lancet 364 (9435) (2004) 685–696, https://doi.org/10.1016/S0140-6736(04)6895-5.

[15] R.C. Pasternak, S.C. Smith, C.N. Bairey-Merz, S.M. Grundy, J.I. Cleeman, C. Lenfant, ACC/AHA/NHLBI clinical advisory on the use and safety of statins, Circulation 106 (8) (2002) 1024–1028, https://doi.org/10.1161/01.CIR.0000032466.44170.44.

[16] B.A. Parker, J.A. Capizzi, A.S. Grimaldi, P.M. Clarkson, S.M. Cole, J. Keadle, S. Chipkin, L.S. Pescatello, K. Simpson, C.M. White, P.D. Thompson, Effect of statins on skeletal muscle function, Circulation 127 (1) (2013) 96–103, https://doi.org/10.1161/CIRCULATIONAHA.112.136101.

[17] Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet 360 (9326) (2002) 7–22, https://doi.org/10.1016/S0140-6736(02)13636-7.

[18] K. El-Salem, B. Ababneh, S. Rudnicki, A. Malkawi, A. Alrefai, Y. f Khader, R. Saadeh, M. Saydam, Prevalence and risk factors of muscle complications secondary to statins, Muscle Nerve 44 (2011) 877–881, https://doi.org/10.1002/mus.22205.

[19] D.J. Graham, J.A. Staffa, S.E. Andrade, S.D. Schech, L. LaGrenade, J.H. Gurwitz, K. A. Chan, M.J. Goodman, R. Platt, Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs, JAMA 292 (2004) 2585–2590, https://doi.org/10.1001/jama.292.21.2585.Epub2004Nov22.

[20] D. Gaist, L.A. Rodríguez, C. Huerta, J. Hallas, S.H. Sindrup, Lipid-lowering drugs and risk of myopathy: a population-based follow-up study, Epidemiology 12 (2001) 565–569, https://doi.org/10.1097/00001648-200109000-00017.

[21] R.C. Pasternak, S.C. Smith Jr., S.M. Grundy, J.I. Cleeman, C. Lenfant, American College of Cardiology; American heart association; national heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins, J. Am. Coll. Cardiol. 40 (3) (2002) 567–572, https://doi.org/10.1016/s0735-1097(02)02030-2.

[22] J. Shepherd, D. Hunninghake, S. Harris, H. Hutchinson, J. Pears, A review of the safety profile of rosuvastatin in an international phase II/III clinical trial program, in: Paper Presented at the XIV International Symposium on Drugs Affecting Lipid Metabolism, September 2001. New York.